BridgeBio Pharma

We move at the speed of patient need.

We exist to bring meaningful medicines to people living with genetic conditions. $BBIO

[BridgeBio Pharma @BridgeBioPharma]

We will report Q3 2026 financial results and a business update after market close Thurs, Oct 29. Conference call at 4:30pm ET same day. Details: https://t.co/dLkmy5z3X4

[BridgeBio Pharma @BridgeBioPharma]

"A major problem for rare disease research is funding." – Guangping Gao, M.D., UMass Chan Medical School. Noa is one of more than 30 million Americans living with a rare disease. Behind that number are families still waiting. Watch the full video on our Insights page: https://t.co/54hpJoBdL3

[BridgeBio Pharma @BridgeBioPharma]

Allelic series: the human genetics evidence that helps you pick the right drug target. About 1 in 10 drugs that reach clinical testing are approved, and most failures are good molecules aimed at the wrong target. Try our new interactive feature: https://t.co/voPj4nfhnn

[BridgeBio Pharma @BridgeBioPharma]

Heart failure science, live in Phoenix. 🫀

We recently attended the @HFSA (#HFSA2026) Annual Scientific Meeting in Phoenix.

Conferences like this are where the heart failure community comes together to share new data, trade ideas, and keep the focus on patients. We were glad to be there listening, learning, and connecting with clinicians, researchers, and advocates working to improve outcomes.

Thank you to everyone who stopped by to say hello. We enjoyed hearing what’s on your mind and look forward to continuing the conversation on ATTR-CM.

[BridgeBio Pharma @BridgeBioPharma]

That’s a wrap on #ASBMR2026. We shared Phase 3 CALIBRATE data on investigational encaleret in ADH1, family genetic testing findings with the HypoPARAthyroidism Association, and infigratinib research in achondroplasia. Thank you to the investigators, participants and families.

[BridgeBio Pharma @BridgeBioPharma]

For people living with chronic #hypopara and their caregivers, learning about a #clinicaltrial begins with clear, accessible information. Take a closer look at what researchers hope to learn through the RECLAIM-HP Study and how the study medicine is given.

[BridgeBio Pharma @BridgeBioPharma]

“The first thing that pops up is that life expectancy is about ten. That was when we realized how bad it really was.” – Lori Greenwood, Noa's mother. Noa is one of more than 30 million Americans living with a rare disease. Behind that number are families still waiting. Watch the full video on our Insights page: https://t.co/54hpJoBdL3

[BridgeBio Pharma @BridgeBioPharma]

Those living with limb-girdle muscular dystrophy (LGMD) often prioritize maintaining their day-to-day functioning. Learn the possible signs of LGMD and how recognizing them could lead to earlier diagnosis.

[BridgeBio Pharma @BridgeBioPharma]

At #HFSA2026 in Phoenix, BridgeBio and independent investigators shared new real-world evidence and Phase 3 analyses in ATTR-CM. We're grateful to the investigators, clinicians and, above all, the patients and families whose participation makes this research possible. Learn more: https://t.co/Ciy6u3KxjN

[BridgeBio Pharma @BridgeBioPharma]

Today at #ASBMR2026, we presented new bone turnover and participant-reported outcome data from the Phase 3 CALIBRATE trial of investigational encaleret in ADH1. We also dosed the first participant in RECLAIM-HP, our Phase 3 study of encaleret in chronic hypoparathyroidism. Learn more: https://t.co/9s1cDQEsQ7

[BridgeBio Pharma @BridgeBioPharma]

Thank you, #NMSG2026! The smaller setting gave us time for detailed conversations with the neuromuscular community about our Phase 3 FORTIFY study in LGMD2I/R9. Your partnership moves this work forward.

[BridgeBio Pharma @BridgeBioPharma]

That's a wrap on #WMS2026! We had a full room at our symposium and great talks with clinicians, researchers and advocates from the U.S. and Japan. Thank you to everyone who joined us. We're grateful for this community and the partnerships moving LGMD care forward.

[BridgeBio Pharma @BridgeBioPharma]

This #DwarfismAwarenessMonth, hear from Gwyn, host of A Little View, about growing up with #achondroplasia, body image, and finding strength in community on the #OnRarePodcast. "You're still a person; you still have feelings." 🎧 https://t.co/xMbveVOTUd

[BridgeBio Pharma @BridgeBioPharma]

People living with chronic #hypopara and their caregivers may have questions about clinical #research and what researchers hope to learn. The RECLAIM-HP Study aims to learn whether the study medicine—taken by mouth twice a day—can help keep blood and urine calcium levels in the normal range.

[BridgeBio Pharma @BridgeBioPharma]

We’re proud to share that Christine Zhang, Executive Director, Evanesco Program Lead at BridgeBio, has been named to this year’s BioSpace’s 40 Under 40 cohort.

Christine’s leadership embodies the innovative thinking and scientific conviction that drives our mission to deliver transformative medicines where they are needed most.

Congratulations, Christine!

Read more: https://t.co/dgsp35jPim

[BridgeBio Pharma @BridgeBioPharma]

The FDA has accepted our NDA for infigratinib in achondroplasia. PDUFA date: February 4, 2027. If approved, it would be the first oral therapy for children with achondroplasia. $BBIO
https://t.co/faPY57768e

[BridgeBio Pharma @BridgeBioPharma]

Heading to #ASBMR2026 in Boston! We'll present participant-reported outcomes and bone data from our Phase 3 CALIBRATE trial of encaleret in #ADH1, plus new genetic testing data. Details: https://t.co/wSnO4l40BZ

[BridgeBio Pharma @BridgeBioPharma]

We will be at #HFSA2026 in Phoenix, Oct 9–12. At @hfsa, we will share updates in ATTR-CM, including an independent comparative real-world analysis using Epic Cosmos EHR data.
Full schedule: https://t.co/uL8SrO5Eth

[BridgeBio Pharma @BridgeBioPharma]

Muscle weakness has a long list of possible causes. Genetic testing is what names the one you have. Neha Gandhi of BridgeBio Neuromuscular and Kelly Brazzo of CureLGMD2i went Behind the Mystery on @lifetimetv on #LGMD diagnosis, advocacy and community. Watch the replay: https://t.co/LYHg0zuc68

[BridgeBio Pharma @BridgeBioPharma]

For people living with chronic #hypoparathyroidism—and the families and care teams who support them—learning about a #ClinicalTrial may begin with questions. Swipe through for an introduction to the RECLAIM-HP Study, what researchers hope to learn, and where to find more information.